Two types of circulating endothelial progenitor cells in patients receiving long term therapy by HMG-CoA reductase inhibitors

Autor: Joseph-Philippe Etievent, Nicolas Meneveau, Frédéric Deschaseaux, Pierre-Emmanuel Falcoz, Nursen Mersin, Pierre Tiberghien, Zohair Selmani, Alfred Penfornis, Sidney Chocron, C. Kleinclauss, Jean-Pierre Kantelip, Siamak Davani

Publikováno v: European Journal of Pharmacology
European Journal of Pharmacology, Elsevier, 2007, 562 (1-2), pp.111-8. ⟨10.1016/j.ejphar.2007.01.045⟩
European Journal of Pharmacology, Elsevier, 2007, 562 (1-2), pp.111-8. 〈10.1016/j.ejphar.2007.01.045〉

International audience; 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely used to decrease cholesterol synthesis and are well established to reduce vascular diseases. Recently, it has been proposed that statins

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10f724e9793befc717dc74b9fd9da39a
https://pubmed.ncbi.nlm.nih.gov/17320859